FDA NEWS

Biotech-Stock Mailbag: Panacos, Indevus - Street.Com
Indevus Pharmaceuticals IDEV and the recent regulatory setback to its long-acting, injectable testosterone product Nebido is on the mind of Robert E., who writes: "I was surprised by the FDA [Food and Drug Administration] response to Nebido as it is
Source: www.thestreet.com

FDA OKs device tested on Christopher Reeve - USA Today
CLEVELAND (AP) — The U.S. Food and Drug Administration has approved a medical device tested on actor Christopher Reeve to help paralyzed people breathe without a ventilator. The device, made by Synapse Biomedical Inc. of Oberlin, Ohio, electrically
Source: www.usatoday.com

FDA sued for failure to act on risky painkiller - Los Angeles Times
WASHINGTON -- A prescription painkiller sold under such names as Darvon and Darvocet is too risky to stay on the market, a consumer advocacy group argued Thursday in suing the Food and Drug Administration. Public Citizen petitioned the FDA two years
Source: www.latimes.com

FDA says deaths with heart imaging drugs continue - CNN Money
NEW YORK (Associated Press) - Despite previous warnings to physicians, drugs used to improve medical images of the heart continue to cause fatal side effects, regulators said Friday. The Food and Drug Administration said that since October it has
Source: money.cnn.com

RPT-INTERVIEW-US FDA seeks India post for food, drug checks - Reuters AlertNet
WASHINGTON, June 19 (Reuters) - The U.S. Food and Drug Administration hopes to establish operations in India by year's end to better police the growing volume of food, medicines, medical devices and animal feed exported to the United States, a top
Source: www.alertnet.org

UPDATE: Long Delay Seen For Merck's Cholesterol Drug - CNN Money
Merck & Co. (MRK) was dealt another setback in its attempt to bring a new cholesterol drug to market after U.S. regulators asked for more information, which could delay the drug's launch for five years. News of the delay comes two months after the U
Source: money.cnn.com

Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin - MSN MoneyCentral
Merck & Co., Inc. today provided an update on the regulatory status in the United States of its investigational medicines MK-0524A (ER niacin/ laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin) for the treatment of primary
Source: news.moneycentral.msn.com

Industry backs FDA supplement clamp-down - Nutra Ingredients USA
20-Jun-2008 - The dietary supplements industry has applauded a move by the Food and Drug Administration (FDA) to clamp down on products making bogus cancer cure claims. FDA this week said it had written to 23 companies and two foreign individuals
Source: www.nutraingredients-usa.com